Clinical Trial Update: To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the pharmacokinetics, safety, and tolerability of efanesoctocog alfa (BIVV001) in adults with Von Willebrand disease types 2N and 3 has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• efanesoctocog alfa (BIVV001) (efanesoctocog alfa)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Von Willebrand's Disease (VWD) | Phase 1 | Status: COMPLETED